Physician profile
Margaret W Perrin
NPI 1528281177
$3,010.42
in general payments reported to CMS, 2019-2025
26 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $170 · 2021: $321 · 2022: $529 · 2023: $449 · 2024: $654 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.94 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.59 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $383.97 | 2019-2021 | |
| Pfizer INC. | $228.84 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $178.97 | 2019-2022 | |
| Lilly USA, LLC | $169.29 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Genentech USA, INC. | $157.29 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $148.50 | 2019-2024 | |
| Biogen, INC. | $144.63 | 2019-2022 | |
| Eisai INC. | $136.02 | 2019-2025 | |
| Neurelis, INC. | $111.82 | 2020-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $101.95 | 2022 | |
| Sumitomo Pharma America, INC. | $95.71 | 2023-2024 | Aptiom |
| Genzyme Corporation | $79.23 | 2019-2022 | |
| Ucb, INC. | $48.17 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $46.51 | 2024-2025 | Crexont, Ongentys |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $33.13 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $25.13 | 2025 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $24.27 | 2025 | Horizant |
| Vertical Pharmaceuticals, LLC | $21.09 | 2019 | |
| Bausch Health US, LLC | $18.72 | 2021 | |
| Mdd US Operations, LLC | $18.31 | 2019 | |
| Upsher-Smith Laboratories LLC | $17.94 | 2019 | |
| Adamas Pharmaceuticals, INC. | $14.99 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.95 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.99 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Perrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.